3SBio, (FRA:YFK) Debt-to-Asset : 0.28 (As of Dec. 2016)

View and export this data going back to . Start your Free Trial

What is 3SBio, Debt-to-Asset?

3SBio,'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was €71.0 Mil. 3SBio,'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2016 was €348.1 Mil. 3SBio,'s Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2016 was €1,512.3 Mil. 3SBio,'s debt to asset for the quarter that ended in Dec. 2016 was 0.28.

3SBio, Debt-to-Asset Historical Data

The historical data trend for 3SBio,'s Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio, Debt-to-Asset Chart

3SBio, Annual Data

Trend

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec14

Dec15

Dec16

Debt-to-Asset

Get a 7-Day Free Trial

0.27

0.06

0.28

3SBio, Semi-Annual Data
	Jun06	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16
Debt-to-Asset	Get a 7-Day Free Trial															0.27	0.11	0.06	0.33	0.28

Competitive Comparison of 3SBio,'s Debt-to-Asset

For the Biotechnology subindustry, 3SBio,'s Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

3SBio,'s Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio,'s Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where 3SBio,'s Debt-to-Asset falls into.

3SBio, Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

3SBio,'s Debt-to-Asset for the fiscal year that ended in Dec. 2016 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(71.028	+	348.069)	/	1512.296
	=	0.28

3SBio,'s Debt-to-Asset for the quarter that ended in Dec. 2016 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(71.028	+	348.069)	/	1512.296
	=	0.28

3SBio, (FRA:YFK) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

3SBio, Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of 3SBio,'s Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

3SBio, (FRA:YFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio, Inc. (FRA:YFK) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.3sbio.com

3SBio Inc is engaged in the healthcare sector based in China. It is a pharmaceutical products company and its core activities pertain to developing, manufacturing and marketing biopharmaceuticals. Its portfolio of products comprises of TPIAO and Yisaipu. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world and Yisaipu is a TNF inhibibator product and accounts for the major share in the pharmaceutical industry in China. Most of the company's activities are focused on China while having a minor footprint in a foreign land.

3SBio, (FRA:YFK) Headlines

No Headlines